A Randomised Control Trial To Evaluate Whether Zoledronate Prevents Bone Loss In Acute Exacerbations Of Multiple Sclerosis - Zoledronate in multiple sclerosis
- Conditions
- Bone loss in patients with Multiple Sclerosis (MS) who require large short term doses of methylprednisolone for exacerbations of their disease.MedDRA version: 9.1Level: LLTClassification code 10048393Term: Multiple sclerosis relapseMedDRA version: 9.1Level: LLTClassification code 10065687Term: Bone loss
- Registration Number
- EUCTR2008-005304-93-GB
- Lead Sponsor
- orth Bristol Trust
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- Not specified
Age 18-65 with established MS
Acute flare-up requiring treatment with a corticosteroid
Able to attend for study investigations and assessments
Willing and able to provide informed consent
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Previous diagnosis of osteoporosis
Bone active therapy within previous 12 months (excluding calcium and low dose vitamin D), previous treatment with bisphosphonate at any time.
Associated disorder which may influence bone metabolism
Moderate to severe renal impairment (creatinine>150)
Cardiac failure
Possibility of pregnancy
Breast feeding
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method